Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Paul J. Fudala"'
Publikováno v:
Drug and Alcohol Dependence Reports, Vol 6, Iss , Pp 100133- (2023)
Buprenorphine-based medications were first approved by the United States Food and Drug Administration in 2002 for the treatment of opioid dependence, or opioid use disorder (OUD) as the condition is presently known. This regulatory milestone was the
Externí odkaz:
https://doaj.org/article/ed50a4562a10446786fbf7f6b131e43f
Autor:
Vishaal Mehra, James L. Andersen, Michael J. Biunno, Jelena Kunovac, Walter Ling, Barbara R. Haight, Saleem Ishaque, David R. Hassman, Gregory Seal, Scott Daniel Segal, Amanda S. Garofalo, Jesse M. Carr, Valentin Isacesu, Rakesh Ranjan, Ricky Stuart Mofsen, Otto R. Dueno, Kent Steven Hoffman, Paul J. Fudala, Brent Boyett, Shishuka Malhotra, Lawrence S. Levinson, Céline M. Laffont, Peter Paul Ventre, Eduardo Cifuentes, Sandra Daniela Duarte-Sckell, Scott Robert Bartley, Genie L. Bailey, Richard D. Knapp, Gita G. Pujari, Kyle M. Kampman, Rajinder Shiwach, Christian Heidbreder, Vijay R Nadipelli, Daniel Rutrick, Y Zhao, Rishi Kakar, Katharina Wiest, Marvin Lane Peyton, David P. Walling, Susan M Learned, Joseph A. Kwentus, Amit K. Vijapura, Haydn Mikel Thomas, Boyde J. Harrison, Mark K. Greenwald, George Konis
Publikováno v:
The Lancet. 393:778-790
RBP-6000, referred to as BUP-XR (extended-release buprenorphine), is a subcutaneously injected, monthly buprenorphine treatment for opioid use disorder. BUP-XR provides sustained buprenorphine plasma concentrations to block drug-liking of abused opio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d956456416ef2fa898c563ec73fed86b
https://doi.org/10.1016/s0140-6736(18)32259-1
https://doi.org/10.1016/s0140-6736(18)32259-1
Autor:
Anne Andorn, Paul J. Fudala
Publikováno v:
Substance Use Disorders
Buprenorphine is a mu-opioid partial agonist that was first developed as a parenteral analgesic and subsequently as a treatment for opioid dependence. In the United States, the first two products approved by the US Food and Drug Administration (in 20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a26d4c33b5194fea7e371c5f3c64511
https://doi.org/10.1093/med/9780190920197.003.0009
https://doi.org/10.1093/med/9780190920197.003.0009
Autor:
Barbara R. Haight, Norma Lynn Fox, Sunita Shinde, Anne Andorn, David R. Hassman, Paul J. Fudala, Susan M Learned, Christian Heidbreder, Vijay R Nadipelli, Daniel Rutrick, Y Zhao
Publikováno v:
Journal of Clinical Psychopharmacology
Supplemental digital content is available in the text.
Background BUP-XR (RBP-6000 or SUBLOCADE) is the first Food and Drug Administration–approved subcutaneously administered monthly extended-release buprenorphine medication for the treatment
Background BUP-XR (RBP-6000 or SUBLOCADE) is the first Food and Drug Administration–approved subcutaneously administered monthly extended-release buprenorphine medication for the treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e7f24f63585d4b3e1294bd57656ffd4
https://pubmed.ncbi.nlm.nih.gov/32282418
https://pubmed.ncbi.nlm.nih.gov/32282418
Autor:
Susan M Learned, Lori McLeod, Y Zhao, Christian Heidbreder, Anne Le Moigne, Lauren Nelson, Katharina Wiest, Brent Boyett, Paul J. Fudala, Warren K. Bickel
Publikováno v:
Drug and Alcohol Dependence. 229:109057
Background This work evaluated the psychometric properties of the single-item Opioid Craving Visual Analog Scale (OC-VAS) for opioid use disorder (OUD). Methods Psychometric evaluation of the OC-VAS (range: 0–100 mm) was supported by Subjective Opi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2be2a592de22f993d30df503e6a6b60f
https://doi.org/10.1016/j.drugalcdep.2021.109057
https://doi.org/10.1016/j.drugalcdep.2021.109057
Autor:
Yongzhen Liu, Paul J. Fudala, Philip Twumasi-Ankrah, J. P. Jones, Azmi Nasser, Mark K. Greenwald, Christian Heidbreder, Bradley Vince
Publikováno v:
Journal of Clinical Psychopharmacology. 36:18-26
A major goal for the treatment of opioid use disorder is to reduce or eliminate the use of illicit opioids. Buprenorphine, a μ-opioid receptor partial agonist and kappa opioid receptor antagonist, is now being developed as a monthly, sustained-relea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abf1bb88a8290a399d6768e9befcb824
https://doi.org/10.1097/jcp.0000000000000434
https://doi.org/10.1097/jcp.0000000000000434
Autor:
Paul J. Fudala, Study Investigators, Walter Ling, Amanda S. Garofalo, Susan M Learned, Barbara R. Haight, Y Zhao, Christian Heidbreder, Vijay R Nadipelli, Céline M. Laffont, Mark K. Greenwald
Publikováno v:
SSRN Electronic Journal.
Background: RBP-6000 is a subcutaneously injected, extendedrelease, monthly treatment for opioid use disorder (OUD). RBP 6000 addresses potential limitations of other OUD treatments by delivering sustained buprenorphine plasma concentrations to block
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ec43f9ac697af44639f3ba4dd54fd6c
https://doi.org/10.2139/ssrn.3228895
https://doi.org/10.2139/ssrn.3228895
Publikováno v:
Journal of Addictive Diseases. 33:289-302
RBP-8000 is a double mutant cocaine esterase that rapidly metabolizes cocaine. This study was conducted to assess the pharmacokinetics of cocaine and cocaine-induced physiological effects in the absence (placebo) or presence of RBP-8000. Twenty-nine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9385f3212960b4e99e107c34da3d9d12
https://doi.org/10.1080/10550887.2014.969603
https://doi.org/10.1080/10550887.2014.969603
Autor:
Christian Heidbreder, Bo Zheng, Azmi Nasser, Roberto Gomeni, Paul J. Fudala, Mark K. Greenwald
Publikováno v:
Clinical Pharmacokinetics. 53:813-824
This study implemented pharmacokinetic/pharmacodynamic modelling to support the clinical development of RBP-6000, a new, long-acting, sustained-release formulation of buprenorphine for the treatment of opioid dependence. Such a formulation could offe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::291e0976f10421b2ebe23bcde2029e4e
https://doi.org/10.1007/s40262-014-0155-0
https://doi.org/10.1007/s40262-014-0155-0